Orelabrutinib Commercialization And ADC Pipeline Will Open New Markets

The significant drop in future P/E and improvement in net profit margin point to enhanced profitability expectations for InnoCare Pharma, supporting the upward revision of the consensus analyst price target from HK$15.61 to HK$17.09. What's in the News HIBRUKA (orelabrutinib) approved by Singapore HSA for relapsed or refractory marginal zone lymphoma; previously approved in China for first-line CLL/SLL and multiple other B-cell lymphoma indications, with National Reimbursement Drug List coverage.

A sharp decline in InnoCare Pharma’s future P/E multiple alongside a modest improvement in net profit margin suggests enhanced growth expectations and profitability, resulting in an increased fair value estimate, with the consensus analyst price target rising from HK$13.51 to HK$14.28. What's in the News InnoCare Pharma's Board of Directors will meet to consider and publish interim results for the six months ended 30 June 2025.

The consensus price target for InnoCare Pharma has increased to HK$13.51, underpinned by notable improvements in net profit margin and higher future P/E expectations. What's in the News InnoCare received IND approval to initiate a clinical trial for its novel B7-H3 targeted ADC (ICP-B794) for various solid tumors, further strengthening its solid tumor pipeline alongside other precision medicine candidates like zurletrectinib.

AnalystConsensusTarget has increased future PE multiple from 46.2x to 52.1x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased future PE multiple from 36.2x to 44.4x.

AnalystConsensusTarget has increased profit margin from 15.6% to 17.9%, decreased future PE multiple from 40.8x to 36.2x and increased shares outstanding growth rate from -0.1% to -0.0%.

AnalystConsensusTarget has decreased future PE multiple from 54.5x to 40.8x.